Literature DB >> 6327823

Differential effect of cyclosporin A on the expression of T and B lymphocyte activation antigens.

H S Lillehoj, T R Malek, E M Shevach.   

Abstract

We have used a monoclonal antibody (Mab) to the interleukin 2 (IL 2) receptor as well as a Mab to the transferrin receptor to analyze the effects of cyclosporin A (CsA) on the induction and expression of these activation antigens on mitogen-stimulated murine T and B lymphocytes. The same concentration (0.25 microgram/ml) of CsA that produced optimal inhibition of the T cell proliferative response to concanavalin A (Con A) was also very effective at inhibiting IL 2 production and the induction of IL 2 responsiveness, as well as the expression of the IL 2 and transferrin receptors when measured 72 hr after mitogen activation. Surprisingly, CsA only minimally inhibited expression of these receptors 24 hr after the addition of mitogen; however, T cell blasts recovered from these cultures failed to respond to IL 2 even though IL 2 receptor expression was only modestly decreased. These results suggest that inhibition of the maturation of receptor expression is secondary to an early effect of CsA in blocking the induction of IL 2 responsiveness or to an arrest in the sequence of events required for maturation of T cells that bear high densities of these receptors. In contrast to the results observed with T lymphocytes, CsA had no effect on the B cell proliferative response to lipopolysaccharide (LPS) or on the induction of the IL 2 and transferrin receptors on activated B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327823

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Analysis of isolated and combined effects of calcium ionophore and phorbol ester on T lymphocyte activation.

Authors:  A F Nóbrega; M S Maldonado; G A Dos Reis
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

2.  Synergistic induction by calcium ionophore and phorbol ester of interleukin-2 (IL-2) receptor expression, IL-2 production, and proliferation in autoimmune MRL/MP-lpr mice.

Authors:  T Koizumi; Y Nakao; T Matsui; Y Katakami; T Nakagawa; T Fujita
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

3.  Differential effect of cyclosporin A on activation signaling in human T cell lines.

Authors:  B Manger; K J Hardy; A Weiss; J D Stobo
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

4.  In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chains.

Authors:  S Caillat-Zucman; L Chatenoud; J F Bach
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

5.  Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation.

Authors:  J C Reed; P C Nowell; R G Hoover
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

Review 6.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

7.  Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.

Authors:  C Boitard; G Feutren; L Castano; M Debray-Sachs; R Assan; J Hors; J F Bach
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 9.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

10.  Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model.

Authors:  C H Mody; G B Toews; M F Lipscomb
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.